SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent momentum and growing number of watchers, with many highlighting upcoming utilities. Community members are expressing bullish sentiment, anticipating further gains and airdrops for NFT holders. The conversation also reflects excitement around staking and the project's overall development.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around its unique rewards system, which distributes Solana ($SOL.X) directly to holders, regardless of price fluctuations. Recent discussions highlight the strength and resilience of the community, with many emphasizing that holding $IMG.X provides passive income superior to traditional investments, while also mentioning a new partnership with Kimbo Slice Jr.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as it joins the S&P 500, sparking excitement and debate about potential short squeezes and future price movement. The community is discussing whether the stock was pumped prior to the announcement and speculating on profit-taking strategies. Some investors express frustration for selling earlier, while others are optimistic about long-term growth.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Traders are focused on whether Strategy will be added to the S&P 500, with the announcement expected soon, while also tracking the company's significant bitcoin holdings as a potential driver. Community discussions revolve around the potential impact of S&P 500 inclusion and the correlation between the stock's performance and Bitcoin's price movements, as well as analyst sentiment. Some traders express concerns about possible manipulation and overinflated expectations, while others remain optimistic about the stock's prospects.

THE COQ FATHER BOSS

THE COQ FATHER BOSS ($BOSSCOQ.X) is trending as the community rallies around the newly launched meme coin, emphasizing holding and anticipating potential major exchange listings. The locked liquidity and Coinbase involvement claims are key talking points, with community members actively encouraging each other to accumulate and 'not sell their COQ'.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to discussions surrounding a report linking Tylenol use during pregnancy to autism, sparking community debate about the validity and potential market impact. Some investors view the dip as a buying opportunity, dismissing the report, while others express concern over potential lawsuits and long-term effects on the company. The broader context includes Kenvue's position as a consumer health company and its relationship with Johnson & Johnson.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to its low float, with traders speculating it could be the next stock to experience a significant squeeze. The community is actively discussing its potential for a rapid price increase, drawing comparisons to other low-float stocks that have recently made substantial moves. A recent land sale boosting NAV is also circulating.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as investors discuss the potential impact of warrant conversions, with some expressing frustration over the company's language regarding possible acquisitions. The community is also weighing oversold signals, awaiting news catalysts, and debating the stock's short-term direction amid broader discussions about solid-state battery technology and market manipulation. Some traders express bullish sentiment while others remain skeptical, citing past performance and management decisions.

Peko is the perfect fusion between the panda, a beloved symbol in Chinese culture, and the Maneki-neko, the iconic Japanese lucky cat. This unique combination embodies prosperity, good fortune, and financial success for those who hold it.  With a distinctive collar inscribed with the name of Trump, currently the President of the United States, Peko symbolizes a message of support and optimism for the crypto world, connecting the international investment community with the belief in luck and financial opportunities.  Holding Peko means having more than just a memecoin — it’s a true digital amulet promising to attract fortune in every investment. Make Peko your partner for financial success!

PEKO

PEKO.X is trending as a "sleeper gem" with a strong community rallying behind it, anticipating a significant pump. Conversations highlight its potential for explosive growth, with many noting the "diamond hands" and "bags packed" in anticipation of a moonshot. The community is focused on its low-cap status and the potential for high returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Shares of Ocugen, Inc. (OCGN) rose 3% on Friday morning after the company reported a better-than-feared first-quarter (Q1) loss.The biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2025-financial">reported</a> a revenue of $1.5 million, up from $1 million in the corresponding quarter of 2024.Loss per share came in at $0.05, unchanged from the corresponding quarter of 2024, and better than the estimated loss of $0.06 per share.The company, which is developing gene therapies for blindness diseases, ended the quarter with cash and restricted cash totaling $38.1 million, compared to $58.8 million as of Dec. 31, 2024. It expects this will provide runway into the first quarter of 2026.CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the U.S. Food and Drug Administration (FDA) requesting approval for the distribution of three of its products in the next three years.“We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vision," he said.On Stocktwits, retail sentiment around Ocugen jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at high levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_9_57_35_AM_png_0d026d6926.webp" alt="Screenshot 2025-05-09 at 9.57.35 AM.png" width="630" height="63"><figcaption>OCGN's Sentiment Meter and Message Volume as of 9:24 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for the stock, citing the three upcoming FDA applications.<stembedurl>https://stocktwits.com/FannyChmelar/message/614075330</stembedurl>Another noted that the low cash reserve is expected in a company not selling products yet.<stembedurl>https://stocktwits.com/Slapshot22/message/614070848</stembedurl><a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is down by 21% this year and 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-faces-moltiply-lawsuit/chiWtc6RblO">Google Faces $3.3B Lawsuit From Italy’s Moltiply Group: Search Giant Disagrees With ‘Exorbitant’ Private Damages Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.

Equity

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.


Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a quarterly earnings report that exceeded revenue expectations.The biopharmaceutical company, which focuses on developing gene therapies for eye diseases, reported a fourth-quarter loss of $0.05 per share, in line with estimates.&nbsp;Revenue was $764,000, down from $1.4 million a year ago due to reduced co-development services, but still well above the $400,000 analysts expected.Ocugen's modifier gene therapy platform includes OCU400, OCU410, and OCU410ST, which target inherited retinal diseases (IRDs) and conditions like dry age-related macular degeneration (dAMD) and Stargardt disease.Its OCU400 is in Phase 3 clinical trials for retinitis pigmentosa (RP) in the U.S. and Canada, with enrollment expected to be completed in the first half of 2025.OCU500, Ocugen's inhaled mucosal COVID-19 vaccine, recently received FDA clearance for an Investigational New Drug (IND) application.&nbsp;The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor a Phase 1 trial evaluating two delivery routes — lung inhalation and nasal spray.To extend its cash runway into the first quarter of 2026 and support ongoing clinical trials, Ocugen secured $65 million in equity and debt financing in the second half of 2024.&nbsp;In May, the company was included in the Russell Index.On Stocktwits, sentiment for Ocugen ended Wednesday higher within the 'bullish' zone, with message volume surging 32%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCGN_sentiment_and_message_volume_as_of_March_5_42ff8160da.png" alt="OCGN sentiment and message volume as of March 5.png" width="1316" height="302"><figcaption>OCGN sentiment and message volume as of March 5 | source: Stocktwits</figcaption></figure>One retail trader said the value of Ocugen's pipeline "is insane and I'll be holding when it comes to fruition."<stembedurl>https://stocktwits.com/SGimvesting/message/606846472</stembedurl>Another was hopeful after pointing out that CEO Shankar Musunuri confirmed NIAID's funding support for OCU500's Phase 1 trial next quarter.<stembedurl>https://stocktwits.com/Hamiltoes/message/606856276</stembedurl>Ocugen's ambitious roadmap targets three potential Biologics License Applications (BLAs) between 2026 and 2028, covering RP, Stargardt, and geographic atrophy (GA).However, Ocugen faces a significant short interest rate of 20.7%, according to Koyfin data.&nbsp;The stock trades 1,033% below the average analyst price target of $6.50, with two analysts rating it a 'buy' and two a 'strong buy.'Shares of Ocugen are down over 33% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Ocugen, Inc. (NASDAQ: OCGN) on behalf of the companys shareholders. Since July 2024, shares of Ocugens stock have declined in value from a trading...

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible...

Peering Into Ocugen's Recent Short Interest

OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm OCGN

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the Class Period...

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) for violations of 10(b) and...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

OCGN
Ocugen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCGN News

OCGN Ocugen Inc